This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aceragen Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

John Taylor

Chief executive officer

US$444.1k

Total compensation

CEO salary percentage	17.5%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	4.2yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Taylor's remuneration changed compared to Aceragen's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$444k	US$78k	-US$23m

Compensation vs Market: John's total compensation ($USD444.06K) is about average for companies of similar size in the German market ($USD438.32K).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.

CEO

John Taylor (52 yo)

less than a year

Tenure

US$444,062

Compensation

Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Taylor	President	less than a year	US$444.06k	no data
Gwen Thomas	Associate Director of Human Resources	no data	no data	no data
Christina Amendola	Director of Human Resources	no data	no data	no data
Brian Jackey	Senior Vice President of Technical Operations	no data	no data	no data
Deepa Nagpal	Global Head of Quality	no data	no data	no data
Shah Rahimian	Medical Director & Global Clinical Lead for Oncology	no data	no data	no data
Joanna Horobin	Advisor	4.2yrs	US$993.93k	no data
Louis Arcudi	Adviser	no data	US$986.13k	no data

4.2yrs

Average Tenure

62yo

Average Age

Experienced Management: V9Z's management team is considered experienced (4.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Taylor	President	less than a year	US$444.06k	no data
Michael Dougherty	Independent Director	4.4yrs	US$89.43k	0.26% $ 5.3k
Vincent Milano	Chair of the Board of Directors	8.8yrs	US$1.43m	0.10% $ 2.0k
Ronald Wooten	Independent Director	less than a year	US$11.88k	no data
Maxine Gowen	Independent Director	7.7yrs	US$66.24k	0% $ 0
Cristina Csimma	Independent Director	4.4yrs	US$60.12k	0% $ 0
V. Sutton	Member of Scientific Advisory Board	no data	no data	no data
Edward Schuchman	Member of Scientific Advisory Board	no data	no data	no data
Atul Chopra	Member of Scientific Advisor Board	no data	no data	14.31% $ 289.2k

4.4yrs

Average Tenure

63.5yo

Average Age

Experienced Board: V9Z's board of directors are considered experienced (4.4 years average tenure).

This company listing is no longer active

Aceragen Management

Management criteria checks 3/4

Key information

Recent management updates

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Insufficient new directors

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Senior VP & COO recently bought €50k worth of stock

Recent updates

Aceragen Files Form 15

Aceragen, Inc.(NasdaqCM:ACGN) dropped from S&P TMI Index

Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Aceragen, Inc. announced delayed 10-Q filing

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra Study

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Idera Pharmaceuticals Receives Notification of Non-Compliance from Listing Qualifications Department of Nasdaq

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Insufficient new directors

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients At Amsterdam UMC

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Idera Pharmaceuticals, Inc. Announces Tilsotolimod Updates

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

Senior VP & COO recently bought €50k worth of stock

Independent Chairman recently bought €83k worth of stock

Senior VP & Chief Medical Officer has left the company

Idera Pharmaceuticals Announces Corporate Updates

Idera Pharmaceuticals, Inc. Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

New 90-day high: €4.48

Idera Pharmaceuticals, Inc. Announces Resignation of R. Clayton Fletcher as Senior Vice President

President recently sold €132k worth of stock

New 90-day high: €4.20

New 90-day high: €2.96

Idera Pharmaceuticals, Inc. Announces Board Changes

Revenue in line with expectations

New 90-day high: €2.54

New 90-day high - €2.26

Idera Pharmaceuticals, Inc. announced that it has received $5.1 million in funding

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age